Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
30th Jan 201511:57 amRNSHolding(s) in Company
28th Jan 201512:05 pmRNSGrant of Options
6th Jan 20157:00 amRNSDirectorate Change
23rd Dec 20147:00 amRNSYear End Update
10th Dec 20147:00 amRNSInnovenn Board Appointment
20th Nov 20147:00 amRNSInnovenn commences production at new facilities
11th Nov 20147:00 amRNSEUR1.4m contract win with US firm
21st Oct 20147:00 amRNSEUR1.2m Contract with Global Pharmaceutical Comp
30th Sep 20147:01 amRNSStrategic Investment in InnoVenn
30th Sep 20147:00 amRNSInterim Results
18th Sep 201411:29 amRNSHolding(s) in Company
8th Sep 20143:00 pmRNSIssue of Consideration Shares
8th Sep 20147:00 amRNSEUR2.4m contract for pan-European coronary study
5th Aug 20147:00 amRNSAcquisition of French CRO
24th Jun 20143:44 pmRNSResult of AGM
24th Jun 20147:00 amRNSAGM Statement
19th Jun 20147:00 amRNSSkin science patent grant
27th May 20142:26 pmRNSDirector's Dealing
16th May 201412:25 pmRNSMajor contract win
16th May 201412:23 pmRNSFinal Results
2nd Apr 201412:21 pmRNSHolding(s) in Company
31st Mar 201411:48 amRNSResult of general meeting
18th Mar 20142:46 pmRNSUpdate on the Acquisition of Evocutis plc
14th Mar 20147:00 amRNSPlacing to raise £1 million & Notice of GM
13th Mar 20141:00 pmRNSUpdate of Evocutis plc acquisition
13th Mar 20141:00 pmRNSResult of AGM and General Meeting
26th Feb 20147:00 amRNSAcquisition of the trading assets of Evocutis PLC
26th Feb 20147:00 amRNSCirc re. Disposal and Notice of GM
13th Jan 20147:00 amRNSUpdate re: Aquisition of German based CRO
9th Dec 20137:00 amRNSAcquisition of Belfast Based CRO
29th Nov 201312:16 pmRNSHolding(s) in Company
31st Oct 20137:00 amRNSAcquisition
11th Oct 20131:31 pmRNSHolding(s) in Company
3rd Oct 201312:55 pmRNSDirector's Dealing
2nd Oct 20132:17 pmRNSChange of Registered Office
27th Sep 20137:00 amRNSInterim Results
23rd Jul 20133:39 pmRNSResult of AGM
13th Jun 20137:00 amRNSFinal Results
17th May 20137:00 amRNSInnovation division launch & co-development
7th May 20138:36 amRNSHolding(s) in Company
26th Apr 20137:09 amRNSProject wins
9th Apr 20137:00 amRNSSenior Management Appointments
14th Mar 20137:00 amRNSBoard Appointment
5th Mar 20131:19 pmRNSHolding(s) in Company
28th Feb 201312:47 pmRNSDirector/PDMR Shareholding
21st Feb 20139:49 amRNSDirector/PDMR Shareholding
7th Feb 20137:00 amRNSVenn Life Sciences expands into Russia
14th Dec 20127:00 amRNSAdmission to trading on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.